Symphogen and Cambridge Antibody Technology sign patent licensing agreement
Symphogen A/S announced that it has entered into a patent license agreement with Cambridge Antibody Technology. Under the terms of the agreement, Symphogen receives a license to use CAT's antibody phage display patents for research purposes and to develop and commercialize a number of therapeutic and diagnostic antibody products. Upon signing the agreement, Symphogen made an upfront payment for the license and exercised its first product license option to develop and commercialize its lead product Sym001. As a condition of exercising this option, Symphogen paid a product license fee and may make future milestone and royalty payments to CAT.
Sym001 is a recombinant, fully human, anti Rhesus D polyclonal antibody which Symphogen is developing for Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of Newborns (HDN). The Company plans to file an IND for initiation of Phase I clinical trials in 2006.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.